Linfoma No Hodgkin

Consenso Nacional de Linfoma no Hodgkin8. Lee EJ, Petroni GR, Schiffer CA, et al.: Brief-durationhigh-intensity chemotherapy for patients withsmall noncleaved-cell lymphoma or FAB L3 acutelymphocytic leukemia: results of cancer and leukemiagroup B study 9251. J Clin Oncol 2001;19: 4014-40229. Thomas DA, Faderl S, O’Brien S, et al.: Chemoimmunotherapywith hyper-CVAD plus rituximab forthe treatment of adult Burkitt and Burkitt-type lymphomaor acute lymphoblastic leukemia. Cancer2006;106: 1569-158010. Magrath I, Adde M, Shad A, et al.: Adults and childrenwith small non-cleaved-cell lymphoma have asimilar excellent outcome when treated with the samechemotherapy regimen. J Clin Oncol 1996;14:925-93411. Mead GM, Sydes MR, Walewski J et al. An internationalevaluation of CODOX-M and CODOX-M alternatingwith IVAC in adult Burkitt’s lymphoma: resultsof United Kingdom Lymphoma Group LY06study. Ann Oncol 2002;13:1264-127412. Lacasce A, Howard O, Lib S et al. Modified magrathregimens for adults with Burkitt and Burkitt-like lymphomas:preserved efficacy with decreased toxicity.Leuk Lymphoma 2004;45:761-76713. Freedman AS, Takvorian T, Anderson KC, et al.:Autologous bone marrow transplantation in B-cellnon-Hodgkin’s lymphoma: very low treatment-relatedmortality in 100 patients in sensitive relapse. JClin Oncol1990; 8: 784-79114. Sweetenham JW, Pearce R, Philip T, et al.: Highdosetherapy and autologous bone marrow transplantationfor intermediate and high grade non-Hodgkin’s lymphoma in patients aged 55 years andover: results from the European Group for Bone MarrowTransplantation. The EBMT Lymphoma WorkingParty. Bone Marrow Transplant 1994;14: 981-987.Bibliografía LTP1. Rizvi MA, Evens AM, Tallman MS, et al.: T-cell non-Hodgkin lymphoma. Blood 2006 ;107: 1255-12642. Harris NL, Jaffe ES, Armitage JO, et al.: Lymphomaclassification: from R.E.A.L. to W.H.O. and beyond.Cancer: Principles and Practice of Oncology Updates1999;13: 1-143. Rüdiger T, Weisenburger DD, Anderson JR, et al.:Peripheral T-cell lymphoma (excluding anaplasticlarge-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. AnnOncol 2002;13: 140-1494. López-Guillermo A, Cid J, Salar A, et al.: PeripheralT-cell lymphomas: initial features, natural history,and prognostic factors in a series of 174 patientsdiagnosed according to the R.E.A.L. Classification.Ann Oncol 1998;9: 849-555. Hoque SR, Child FJ, Whittaker SJ, et al.: Subcutaneouspanniculitis-like T-cell lymphoma: a clinicopathological,immunophenotypic and molecularanalysis of six patients. Br J Dermatol 2003; 148:516-256. Gale J, Simmonds PD, Mead GM, et al.: Enteropathy-typeintestinal T-cell lymphoma: clinical featuresand treatment of 31 patients in a single center. J ClinOncol 2000;18: 795-8037. Daum S, Ullrich R, Heise W, et al.: Intestinal non-Hodgkin’s lymphoma: a multicenter prospective clinicalstudy from the German Study Group on Intestinalnon-Hodgkin’s Lymphoma. J Clin Oncol2003;21: 2740-68. Siegert W, Nerl C, Agthe A, et al.: Angioimmunoblasticlymphadenopathy (AILD)-type T-cell lymphoma:prognostic impact of clinical observations and laboratoryfindings at presentation. The Kiel LymphomaStudy Group. Ann Oncol 1995; 6: 659-6649. Lipford EH Jr, Margolick JB, Longo DL, et al.: Angiocentricimmunoproliferative lesions: a clinicopathologicspectrum of post-thymic T-cell proliferations.Blood 1988; 72: 1674-168110. Jaffe ES: Angioimmunoblastic T-cell lymphoma:new insights, but the clinical challenge remains.Ann Oncol 1995; 6: 631-63211. Bräuninger A, Spieker T, Willenbrock K, et al.: Survivaland clonal expansion of mutating “forbidden”(immunoglobulin receptor-deficient) epstein-barrvirus-infected b cells in angioimmunoblastic t celllymphoma. J Exp Med 2001;194: 927-94012. Siegert W, Agthe A, Griesser H, et al.: Treatment ofangioimmunoblastic lymphadenopathy (AILD)-typeT-cell lymphoma using prednisone with or withoutthe COPBLAM/IMVP-16 regimen. A multicenter study.Kiel Lymphoma Study Group. Ann Intern Med1992;117: 364-37013. Bai RY, Ouyang T, Miething C, et al.: Nucleophosmin-anaplasticlymphoma kinase associated withanaplastic large-cell lymphoma activates thephosphatidylinositol 3-kinase/Akt antiapoptotic signalingpathway. Blood 2000; 96: 4319-432714. Gascoyne RD, Aoun P, Wu D, et al.: Prognostic significanceof anaplastic lymphoma kinase (ALK) proteinexpression in adults with anaplastic large celllymphoma. Blood 1999: 93: 3913-392115. Farcet JP, Gaulard P, Marolleau JP, et al.: HepatosplenicT-cell lymphoma: sinusal/sinusoidal localizationof malignant cells expressing the T-cell receptorgamma delta. Blood 1990;75: 2213-916. Wong KF, Chan JK, Matutes E, et al.: Hepatosplenicgamma delta T-cell lymphoma. A distinctive aggressivelymphoma type. Am J Surg Pathol 1995;19:718-72617. Belhadj K, Reyes F, Farcet JP, et al.: Hepatosplenicgammadelta T-cell lymphoma is a rare clinicopathologicentity with poor outcome: report on a series of21 patients. Blood 2003;102: 4261-426918. François A, Lesesve JF, Stamatoullas A, et al.: Hepatosplenicgamma/delta T-cell lymphoma: a reportof two cases in immunocompromised patients, associatedwith isochromosome 7q. Am J Surg Pathol1997;21: 781-9019. Li CC, Tien HF, Tang JL, et al.: Treatment outcomeand pattern of failure in 77 patients with sinonasalnatural killer/T-cell or T-cell lymphoma. Cancer2004;100: 366-37520. Lee J, Suh C, Park YH, et al.: Extranodal natural killerT-cell lymphoma, nasal-type: a prognostic modelfrom a retrospective multicenter study. J ClinOncol 2006;24: 612-61821. Liang R: Diagnosis and management of primary nasallymphoma of T-cell or NK-cell origin. Clin Lymphoma2000;1: 33-3722. Reimer P, Schertlin T, Rüdiger T, et al.: Myeloablativeradiochemotherapy followed by autologous peripheralblood stem cell transplantation as first-linetherapy in peripheral T-cell lymphomas: first resultsof a prospective multicenter study. Hematol J2004;5: 304-31123. Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al.:Nonhepatosplenic gammadelta T-cell lymphoma: asubset of cytotoxic lymphomas with mucosal or skinlocalization. Blood1998; 91: 1723-173124. Matutes E, Taylor GP, Cavenagh J, et al.: Interferon® Cátedra de Hematología. Abril 2008. Montevideo, Uruguay57